Company intelligence / Profile preview

TyraTech

Morrisville, North Carolina, United Statestyratech.com ↗

Ownership: Private
Development stage: Other

Overview

TyraTech develops and commercializes nature-derived, non-toxic insect and parasite control products for human health, animal health, food safety, and environmental applications. Its portfolio includes head lice treatments ("Vamousse"), DEET-free insect repellents ("Guardian"), red mite controls for poultry production ("PureScience®"), and equine fly sprays ("OutSmart"). The company emphasizes efficacy with improved safety profiles compared to traditional synthetic pesticides. Products are sold through retail chains in the US and Europe. TyraTech operates as a subsidiary of American Vanguard Corporation.

Therapeutic areas: Infectious DiseasesOther
Modalities: Small molecule
Industry: Non-Drug Biotech

Partnerships

MWI Animal Health (US distributor)Brookshire Grocery Company (retail partner)various European distributors

Beyond the preview

Go deeper on TyraTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TyraTech.

Explore the full profile